Patrick S Parfrey, Tilman B Drüeke, Geoffrey A Block, Ricardo Correa-Rotter, Jürgen Floege, Charles A Herzog, Gerard M London, Kenneth W Mahaffey, Sharon M Moe, David C Wheeler, Yumi Kubo, Bastian Dehmel, William G Goodman, Glenn M Chertow
BACKGROUND AND OBJECTIVES: The calcimimetic cinacalcet reduced the risk of death or cardiovascular (CV) events in older, but not younger, patients with moderate to severe secondary hyperparathyroidism (HPT) who were receiving hemodialysis. To determine whether the lower risk in younger patients might be due to lower baseline CV risk and more frequent use of cointerventions that reduce parathyroid hormone (kidney transplantation, parathyroidectomy, and commercial cinacalcet use), this study examined the effects of cinacalcet in older (≥65 years, n=1005) and younger (<65 years, n=2878) patients...
May 7, 2015: Clinical Journal of the American Society of Nephrology: CJASN